Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Mount Sinai Hospital
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
Nov 13, 2018
Compugen Announces Issuance of U.S. Patent for COM902, its TIGIT Antibody Product Candidate for Cancer Immunotherapy
Nov 07, 2018
Compugen Reports Third Quarter 2018 Results
Our optimized process for predictive discovery of novel drug targets
Discovery & development of first-in-class monoclonal antibody therapeutics
Compugen, FROM CODE TO CURE
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
Nov 07, 2018
Compugen Third Quarter 2018 Conference Call
Oct 11, 2018
Bristol-Myers Squibb Clinical Collaboration and Equity Investment Conference Call
Aug 01, 2018
Compugen Second Quarter 2018 Conference Call (note 8:30 AM ET start time)
Click here for more info about partnering with Compugen